Pain – GPCR and Nerve Growth Factor-Based Therapies Offer Strong Potential in Difficult-to-Treat Subtypes
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
The pain therapeutics market has been largely characterized by only incremental product innovation over the last decade, as most market segments continue to be dominated by long-established active pharmaceutical ingredients and mechanisms of action. The moderate-to-severe pain space continues to be dominated by opioids, which are increasingly being reformulated to offer abuse resistance, whereas mild pain is effectively treated with non-steroidal anti-inflammatory drugs (NSAIDs). However, significant unmet needs remain, as chronic pain subtypes—particularly neuropathic pain—do not respond well to existing therapies. This report assesses first-in-class innovation across the pain pipeline.
Scope
There are 909 pipeline programs in active development for pain. What proportion of these products are first-in-class? How does first-in-class innovation vary by development stage and molecular target class?
The market for pain treatment is heavily saturated. Which drug classes are used to treat pain? How do the drug classes in the market compare with those in the pipelines?
Which molecular target classes are prominently represented in the first-in-class pain pipelines? Which first-in-class targets have been identified as most promising for the treatment of pain? Which first-in-class products have prior deal involvement?
Reasons to Buy
Understand the current disease landscape with an overview of etiology, pathophysiology, disease classification and staging systems and epidemiology for major pain subtypes.
Visualize the composition of the pain market in terms of dominant molecule types and molecular targets. This knowledge allows a competitive understanding of gaps in the current market.
Analyze and compare the pain pipeline and stratify by stage of development, molecule type, and molecular target.
Assess the therapeutic potential of first-in-class targets. Using a proprietary matrix, first-in-class products have been assessed and ranked according to clinical potential. Promising first-in-class targets have been reviewed in greater detail.
Recognize commercial opportunities by identifying first-in-class pipeline products for pain that have not yet been involved in licensing or co-development deals, and by analyzing company strategies in prior deals through case studies of key deals for first-in-class pain products.
Table of Contents
Table
Figures
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.